Category: Include on Menu

Medicus Pharma Ltd. (MDCX) has outlined a revised development strategy that makes CD228V, its second-generation antibody-drug conjugate targeting melanotransferrin/CD228, the company’s principal clinical programme. Initial development of CD228V will focus on melanoma, particularly patients with relapsed or refractory disease. The programme has an active U.S. Investigational New Drug application and is being evaluated in a…

IonQ (NYSE:IONQ) shares rose 5.8% on Tuesday after the quantum computing company increased its full-year 2026 revenue guidance following the completion of its acquisition of SkyWater Technology. The company now expects revenue of between $450 million and $460 million for 2026, incorporating SkyWater’s contribution from July 31, when the transaction was completed, through the end…

Inhibrx Biosciences (NASDAQ:INBX) shares gained 6% on Tuesday after the biotechnology company reported encouraging Phase 2 results for INBRX-106 in combination with pembrolizumab in patients with head and neck cancer. Data from the HexAgon study showed a confirmed objective response rate of 48.3% among patients receiving the combination, compared with 26.5% for those treated with…

GE Aerospace (NYSE:GE) said on Tuesday that it has agreed to acquire Consolidated Precision Products from private investment firms Warburg Pincus and Berkshire Partners for $11.75 billion. Consolidated Precision Products, or CPP, manufactures engineered castings and sub-assemblies for commercial aerospace and defence customers. The Cleveland, Ohio-based company employs approximately 6,600 people across more than 20…

Solaris Energy Infrastructure, Inc. (NYSE:SEI) shares rose 6% on Tuesday after the company increased its Adjusted EBITDA guidance for the third and fourth quarters of 2026 and issued an initial forecast for the first quarter of 2027. The company attributed the higher outlook to increased contributions from its core power services operations and performance from…

Intellia Therapeutics (NASDAQ:NTLA) shares rose 8% on Tuesday after the U.S. Food and Drug Administration accepted the company’s Biologics License Application for lonvoguran ziclumeran, or lonvo-z, for hereditary angioedema and granted it Priority Review. The FDA set a Prescription Drug User Fee Act target action date of March 10, 2027. The agency also advised Intellia…

Best Buy (NYSE:BBY) shares fell 2.2% in premarket trading after DA Davidson downgraded the consumer electronics retailer to Neutral from Buy and set a $95 price target. The firm cited valuation following a recovery in Best Buy’s share price, which had moved to within approximately 5% of its new target. According to the supplied information,…

Roivant Sciences (NASDAQ:ROIV) shares rose 22.0% in premarket trading after its Pulmovant subsidiary reported topline results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, or PH-ILD. The results were presented at the European Respiratory Society International Congress 2026 by Professor Marc Humbert of Université Paris-Saclay.…

Ionis Pharmaceuticals (NASDAQ:IONS) shares fell 13.1% to $50.51 in premarket trading as investors continued to assess the Phase 3 trial result for pelacarsen, an RNA-targeted cardiovascular drug licensed to Novartis. Novartis disclosed on September 4 that the Phase 3 Lp(a)HORIZON study did not meet its primary endpoint. The trial enrolled more than 8,300 high-risk patients…

Biohaven Pharmaceutical (NYSE:BHVN) shares fell 1.9% to $15.40 in premarket trading after RBC Capital downgraded the company to Sector Perform from Outperform and lowered its price target to $19 from $23. RBC based the downgrade primarily on valuation following a recovery in Biohaven’s share price. According to the supplied information, the shares have risen approximately…